Dose-Response Effects Of Denosumab, a Novel Subcutaneous RANKL Inhibitor, On The Progression Of Bone Erosion In Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate : Results Of Phase II DRIVE Study-A Twelve Month Placebo Controlled, Randomized, Double Blind Study